OncoCyte Corp OCX.OQ OCX.O is expected to show a fall in quarterly revenue when it reports results on May 12 for the period ending March 31 2025
The Irvine California-based company is expected to report a 28.0% decrease in revenue to $126.75 thousand from $176 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for OncoCyte Corp is for a loss of 24 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for OncoCyte Corp is $4.50, above its last closing price of $2.87.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.44 | -0.43 | -1.93 | Missed | -351.6 |
Sep. 30 2024 | -0.44 | -0.44 | -0.98 | Missed | -124.8 |
Jun. 30 2024 | -0.55 | -0.56 | -0.36 | Beat | 35.6 |
Mar. 31 2024 | -0.65 | -0.67 | -1.13 | Missed | -69.1 |
Dec. 31 2023 | -1.14 | -2.12 | Missed | -86.5 | |
Sep. 30 2023 | -1.00 | -1.01 | -0.81 | Beat | 19.6 |
Jun. 30 2023 | -0.68 | -1.30 | -1.07 | Beat | 17.7 |
Mar. 31 2023 | -1.31 | -1.84 | 0.40 | Beat | 121.7 |
This summary was machine generated May 10 at 00:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。